Innovative Medicines Initiative (IMI) has named Pierre Meulien as executive director, effective from September.
Meulien is currently president and CEO of Genome Canada, a not-for-profit organisation that aims to find new uses for genomics. At the organisation, he successfully secured funding from the Canadian government and leveraged further funding through partnerships.
Commenting on his appointment, Meulien said: “I am delighted to have been selected to lead the second phase of the Innovative Medicines Initiative.
“This unique joint venture will deliver health innovations to millions of European citizens and solidify an important industry based in Europe that will be a source of jobs and growth in all of the member states.”
Prior to joining Genome Canada in 2010, Meulien served as CSO for Genome British Columbia, where he promoted the organisation’s scientific strategy, and prior to that was founding CEO of the Dublin Molecular Medicine Centre.
Carlos Moedas, European commissioner for research, science and innovation, said: “The excellent results coming out of IMI’s projects contribute to improving public health and are stimulating innovation and job creation in Europe. Pierre Meulien’s invaluable experience will help IMI deliver on its ambitious objectives.”